Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Eyes Liquid Biopsy As A Boost To Drug Development, Cancer Monitoring

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche Molecular Diagnostic's top researcher, Walter Koch, discusses the promise of liquid biopsy following FDA's recent approval of its first liquid-biopsy companion diagnostic, Roche's cobas test for the cancer drug Tarceva.

You may also be interested in...



First Blood-Based Lung Cancer EGFR Test Gets FDA Green Light

Roche's cobas EGFR Mutation Test v2 liquid biopsy test is approved to detect genetic mutations linked to drug response in patients with non-small cell lung cancer treated with Tarceva.

FDA To Hold Postponed 3-Day Pediatric Device Workshop In February

The US agency plans to hold a virtual workshop that will use breakout sessions to get stakeholder feedback on specific hurdles preventing more pediatric devices coming to market.

FDA Sets New Restrictions For Authorized N95 Decontamination Systems

After reviewing real-world data, the US agency says the decontamination systems should only be used for compatible facemasks and should not be used to clean a mask more than four times.

Topics

Related Companies

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel